At the last check on Friday, Inovio Pharmaceuticals Inc.’s (NASDAQ:INO) stock traded at $0.45. The average number of shares traded per day over the past five days has been 1,248,917 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0009 fall in that time frame. In the last twenty days, the average volume was 2,549,499, while in the previous 50 days, it was 7,998,496.
Since last month, INO stock retreated -16.41%. Shares of the company fell to $0.4013 on 08/09/23, the lowest level in the past month. A 52-week high of $2.61 was reached on 01/13/23 after having rallying from a 52-week low of $0.38. Since the beginning of this year, INO’s stock price has dropped by -71.06% or -$1.1074, and marked a new high 7 times. However, the stock has declined by -82.70% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
INO stock investors should be aware that Inovio Pharmaceuticals Inc. (INO) stock had its last reported insider trading activity 74 days ago on Jun 05. Zoth Lota S., the Director of the company, disposed of 5,700 shares for $0.56 on Jun 05. It resulted in a $3,192 divestment by the insider. Weiner David B. sold 5,833 shares at an average price of $1.15 on Mar 13. The insider now owns 910,124 shares following the transaction. On Feb 27, Director Weiner David B. sold 11,668 shares at $1.28 apiece. The transaction was valued at $14,935.
Valuation Metrics
The stock’s beta is 0.98. Besides these, the trailing price-to-sales (P/S) ratio of 11.70, the price-to-book (PB) ratio of 0.71.
The latest dividend of $0.0690 per share was paid out, remained unchanged from last year’s $0.0690.
Financial Health
In the three months ended June 29, Inovio Pharmaceuticals Inc.’s quick ratio stood at 3.90, while its current ratio was 3.90, showing that the company is able to pay off its debt. Based on annual data, INO earned $277.84 million in gross profit and brought in $10.26 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. INO’s revenue rose 63.6% to $2.32 million during the quarter, while net income inched up to $2.39 million. While analysts expected Inovio Pharmaceuticals Inc. to report -$0.14 quarterly earnings, the actual figure was -$0.13 per share, beating the consensus estimate by 7.10%. During the quarter, the company generated -$37.14 million in EBITDA. The liabilities of Inovio Pharmaceuticals Inc. were 63.67 million at the end of its most recent quarter ended June 29, and its total debt was $30.76 million. The value of shareholders’ equity is $268.07 million.
Technical Picture
This quick technical analysis looks at Inovio Pharmaceuticals Inc.’s (INO) price momentum. With a historical volatility rate of 72.65%, the RSI 9-day stood at 46.11% on 17 August.
With respect to its five-day moving average, the current Inovio Pharmaceuticals Inc. price is down by -0.20% percent or -$0.0009. At present, INO shares trade -13.01% below its 20-day simple moving average and -50.47% percent below its 100-day simple moving average. However, the stock is currently trading approximately -22.13% below its SMA50 and -79.05% below its SMA200.
Stochastic coefficient K was 31.65% and Stochastic coefficient D was 31.23%, while ATR was 0.0339. Given the Stochastic reading of 38.08% for the 14-day period, the RSI (14) reading has been calculated as 44.83%.
Analyst Ratings
Inovio Pharmaceuticals Inc. downgraded its rating on Inovio Pharmaceuticals Inc. (NASDAQ: INO) to a Hold in a note to investors on November 09, 2022. The analysts firm previously had a Buy rating on the stock.Inovio Pharmaceuticals Inc. (INO) has been rated Hold by analysts. According to 0 brokerage firms, INO is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Inovio Pharmaceuticals Inc. stock as buy, with 0 recommending it as overweight.
